Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 18/20 | 1.00 |
| ▸ | BCL2 | P10415 | 14/20 | 1.00 |
| ▸ | MCL1 | Q07820 | 14/20 | 1.00 |
| ▸ | BCL2A1 | Q16548 | 11/20 | 1.00 |
| ▸ | BAK1 | Q16611 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4384171-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | claimed |
| WO-2023016995-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | claimed |
| WO-2025262113-A1 | COMBINATION THERAPY USING MALT1 AND BCL-2 INHIBITORS AND METHODS OF REDUCING REGULATORY T CELLS | JANSSEN PHARMACEUTICA NV (BE) | 2025-12-26 | — | — | WO | disclosed |
| WO-2025056923-A1 | COMBINATION THERAPY | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2025-03-20 | — | — | WO | disclosed |
| EP-4384171-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN Pharmaceutica NV (BE) | 2024-06-19 | — | — | EP | disclosed |
| CN-116916905-A | Pharmaceutical composition for treating cancer | 塞莱斯蒂亚生物技术股份公司 | 2023-10-20 | — | — | CN | disclosed |
| EP-4255409-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | Cellestia Biotech AG (CH) | 2023-10-11 | — | — | EP | disclosed |
| US-20230074759-A1 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-03-09 | — | — | US | disclosed |
| WO-2023016995-A1 | COMPOSITIONS FOR USE IN TREATING B-CELL MALIGNANCIES | JANSSEN PHARMACEUTICA NV (BE) | 2023-02-16 | — | — | WO | disclosed |
| WO-2022122667-A1 | PHARMACEUTICAL COMBINATIONS FOR TREATING CANCER | CELLESTIA BIOTECH AG (CH) | 2022-06-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230074759-A1 | METHODS AND COMPOSITIONS FOR TREATING B-CELL MALIGNANCIES | MALT1, BCL6, BCL3 | BCL2L1 8/4885BCL2 6/4885MCL1 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.